Siberia | Technology & innovation

Nanotech to normalize blood pressure?

7 May '19
Biologists in Novosibirsk, in Siberia, have developed special nanoparticles that are said to be able to lower blood pressure, and are reported to have successfully tested the drug candidate on hypertension afflicted rats.

In a recent update Asya Levina, a researcher at the Novosibirsk State University (NSU), was quoted as saying that their solution is a system that consists of nanoparticles and short DNA molecules. The former help the latter enter cells and bond with messenger ribonucleic acid (mRNA), thus preventing protein from forming. That results in no increase in the number of receptors on the cells, and the patient does not develop arterial hypertension.

Reports by the World Health Organization (WHO) list cardiovascular diseases, including infarcts, strokes and chronic heart failures, as the number one natural killer globally. The diseases claim about 17 million people each year, and most of the victims hit their death road by developing chronic high blood pressure.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content

Locations: Novosibirsk

Tags: nanoparticles (14) / Novosibirsk State University (10) / hypertension (1) / blood pressure (0) / Asya Levina (0) /

Latest News: Siberia
14 Jun '19 | Technology & innovation
8 May '19 | Technology & innovation
7 May '19 | Technology & innovation
4 Feb '19 | Technology & innovation

Feature stories

26 May '19
This article has been written by Carl Burch, an MBA,...
4 Apr '19
Russian scientists have come up with what they say is...
29 Jan '19
Russian biologists and biophysicists have developed...
Search (News archive - 21385)
Marchmont News

Latest News

19 Jul '19
Rostelecom, the national telecom operator, is...
18 Jul '19
Skolkovo Digital, a Skolkovo Foundation investment...
17 Jul '19
The Russian government is considering a package of...

Most read stories from last week

19 Jul '19
Rostelecom, the national telecom operator, is...